Why this comparison needs care
“Compounded versus brand” is usually framed as a price question. The price difference is real and it is set out below, but it is the last difference on the list, not the first, because it follows from all the others. A compounded GLP-1 medication and an FDA-approved one share an active ingredient and differ in who makes them, what review they have been through, how they are packaged and measured, what evidence exists for them, and what the FDA says about each. This guide takes those differences one at a time, as the FDA and the product labels state them, so that the price comparison at the end means something.
This is general information and not medical advice. Personalized Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to Wegovy®, Ozempic®, Zepbound® or Mounjaro®. Brand names are trademarks of their respective owners, and Bodi Envi is not affiliated with them. Your licensed provider is the person to ask about which, if either, is appropriate for you.
Approval and review
The branded products are FDA-approved. Wegovy® and Ozempic® contain semaglutide; Zepbound® and Mounjaro® contain tirzepatide. Their manufacturers ran the clinical trials, submitted the data, and received approval for the specific indications their prescribing information sets out. The FDA reviewed the safety and effectiveness evidence, the formulation, the manufacturing and the labelling before any of them went on sale, and each carries a label that is itself an FDA-approved document.
A compounded medication has been through none of that. The FDA’s human drug compounding page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. Its compounding questions and answers page adds that a compounded drug is not a generic either: a generic is approved under a specific section of the law and has been found equivalent to the brand, and a compounded drug is neither. The FDA’s stated position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that unnecessary use may expose patients to potentially serious health risks, because poor compounding practices can result in contamination or a drug that contains too much or too little active ingredient.
This is the difference from which the others follow. Everything below is a consequence of one product having been reviewed and the other not.
Who makes it and under what oversight
The branded products are manufactured at scale by their makers in facilities the FDA inspects, under current good manufacturing practice requirements.
A compounded product is made by a compounding pharmacy for an individual patient. The FDA’s questions and answers page describes two kinds. State-licensed pharmacies operating under section 503A of the federal law are overseen day to day primarily by state boards of pharmacy, must compound on the basis of a patient-specific prescription, and are not subject to current good manufacturing practice requirements. Outsourcing facilities registered under section 503B are primarily overseen and inspected by the FDA and are subject to those requirements. Bodi Envi’s prescriptions go to third party U.S. 503A licensed compounding pharmacies, and Bodi Envi publishes that applicable state boards of pharmacy regulate and inspect them and that their operations are subject to applicable U.S. Pharmacopeia standards.
The FDA’s questions and answers page also makes a point about telehealth that applies to any platform, Bodi Envi included: consumers who purchase compounded drugs online may not know the identity of the compounder that produced the drug, including whether it is appropriately licensed and regulated. Bodi Envi names VialsRx as its current pharmacy partner for applicable GLP-1 prescriptions, notes that availability may vary by program and location, and says the prescription label and your care team will confirm the pharmacy that applies to your treatment.
Pens versus vials
The branded products come as devices that deliver a fixed dose. The Wegovy® label describes single-dose pens and syringes at each strength and a multi-dose pen that delivers four weekly doses; the Zepbound® label describes single-dose pens and vials and a multi-dose pen. The dose is set by the device, and the device was part of what the FDA reviewed.
Personalized Compounded semaglutide or tirzepatide typically comes as a vial of solution that the patient draws up with a syringe, though the presentation depends on the pharmacy. The concentration can differ from one pharmacy to another, and the dose is measured by the person injecting it. That is the origin of the FDA’s most specific concern about compounded GLP-1 drugs. Its statement dated September 1, 2026 reports multiple adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, resulting from patients measuring and self-administering incorrect doses and from providers miscalculating doses. It also reports adverse events in patients prescribed personalized compounded semaglutide or tirzepatide in doses beyond what the approved label describes.
The practical consequence is that a compounded prescription puts more of the measuring on the patient. Following the pharmacy’s instructions exactly, using a new sterile needle and syringe each time, and asking the care team before injecting anything you are unsure about is not optional with a vial in the way it can feel optional with a pen.
Salt forms
The FDA’s statement raises a difference that does not exist with the branded products at all. It says the agency is aware that some semaglutide products sold by compounders may be salt forms, semaglutide sodium and semaglutide acetate, which are different active ingredients from the one used in the approved drugs. The agency states that it does not have information on whether these salts have the same chemical and pharmacological properties as the active ingredient in the approved drug, and that it is not aware of any lawful basis for their use in compounding.
A patient cannot tell a salt form from the base molecule by looking at a vial. It is a question to ask, and the answer should come from the pharmacy label or the pharmacy itself. Bodi Envi does not compound and does not manufacture; the pharmacy that fills your prescription is the party that can state what is in it.
Evidence
The trials that established what these molecules do were run on the branded products. STEP 1 studied Wegovy® at 2.4 mg for 68 weeks; SURMOUNT-1 studied Zepbound® at 5, 10 and 15 mg for 72 weeks. The prescribing information for each product reports what those and other trials found, including the frequencies of side effects, and every clinical claim on this site comes from those labels or those papers.
No trial of comparable size has been run on personalized compounded semaglutide or tirzepatide. The FDA’s statement notes that many of the adverse events it has received for compounded products appear consistent with those of the approved versions, but also that pharmacies operating under 503A are not required by federal law to submit adverse events to the FDA, so reports are likely underrepresented. When this site reports a label or trial figure, it is reporting evidence about the approved product. Whether it carries over to a compounded vial is not something anyone has shown.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the FDA says to check for
The FDA’s statement lists warning signs of an unsafe seller of GLP-1 drugs, and they double as a checklist of what a legitimate compounded program should look like by contrast. The signs it names are a claim that the compounded drug is the same as an FDA-approved drug; prices that seem too good to be true; medicine that looks different from what you previously received or arrives damaged or without instructions; no screening and prescription by a licensed doctor before providing medicine; no licensed doctor available to answer questions afterwards; spelling errors or wrong pharmacy addresses on the label; and a pharmacy name that might be fraudulent. The agency also reports fraudulent products labelled with the names of pharmacies that do not exist or that did not make them, and products sold with dosing instructions but falsely labelled for research purposes.
Its recommendations are to obtain a prescription from a licensed provider and to fill it at a state-licensed pharmacy.
Price, as of September 2026
With all of the above in view, the numbers. Brand list prices come from the manufacturers’ own pricing pages, checked in September 2026, and both manufacturers define a list price as the price set before discounts and rebates and say that what a patient pays largely depends on their insurance. Bodi Envi’s prices come from its Plans page.
| Product | Published price | Source |
|---|---|---|
| Wegovy® pen | $1,349.02 per package, list price, as of September 2026 | NovoCare, explaining list price |
| Ozempic® pen | $1,027.51 per pen, list price, as of September 2026 | NovoCare, explaining list price |
| Zepbound® | $499 to $1,086.37 per fill, list price, as of September 2026 | Lilly pricing information |
| Mounjaro® | $1,112.16 per fill, list price, as of September 2026 | Lilly pricing information |
| Bodi Envi personalized compounded semaglutide | $155 per month billed monthly, $125 per month on a twelve month plan | Bodi Envi Plans page |
| Bodi Envi personalized compounded tirzepatide | $229 per month billed monthly, $175 per month on a twelve month plan | Bodi Envi Plans page |
A few notes on reading the table. The units differ: the Wegovy® label describes a package as four single-dose pens, Lilly’s pages define a fill as a 28 day month of up to four pens, and Bodi Envi’s figure is a month of a program. Both manufacturers publish programs below list. NovoCare’s page describes a savings offer for commercially insured patients and self pay pricing for the Wegovy® pen and tablet with an introductory period, and Lilly’s page describes a savings card for commercially insured patients and a direct to patient price for cash paying patients. Those offers carry their own terms and end dates and the cost guides on this site set them out in full. And Bodi Envi’s price is a program price that includes the assessment, provider review, messaging with the care team, a GLP-1 ebook and diet plan, and the medication when prescribed, while a list price covers the medication alone.
The gap is large, and it is a consequence of everything above. A compounded product has not been through FDA review, is made by a pharmacy for one patient rather than at scale, and is measured by the patient from a vial. The lower price reflects that difference in what is being bought, not a discount on the same thing.
How Bodi Envi’s program approaches it
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not sell, supply or represent branded medications. Brand names appear on this site only to explain that compounded medications are not equivalent to FDA-approved products. Clinical services for applicable programs are provided by Wasef Health, PC, and a licensed provider decides independently whether treatment is appropriate for each patient. Prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies.
Bodi Envi’s published prices are the same at every dose, since for applicable programs pricing does not increase based solely on dosage strength, and medication is included only when a licensed provider determines treatment is appropriate and issues a prescription. Completing an assessment does not guarantee one. Whether a compounded product, a branded product or neither is right for you is your provider’s decision, made with your health history in front of them; this guide is general information and not medical advice, and the trials cited studied the branded products and not compounded versions.